Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ)
CNY 33.48
(-2.08%)
CNY 33.48
(-2.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 335.78 Million CNY | 14.93% |
| 2022 | 271.64 Million CNY | 1.15% |
| 2021 | 263.52 Million CNY | 36.38% |
| 2020 | 198.66 Million CNY | 11.67% |
| 2019 | 180.6 Million CNY | -0.69% |
| 2018 | 164.63 Million CNY | -15.87% |
| 2017 | 183.83 Million CNY | -5.49% |
| 2016 | 225.36 Million CNY | 51.49% |
| 2015 | 141.37 Million CNY | -10.97% |
| 2014 | 167.04 Million CNY | 345.41% |
| 2013 | 34.51 Million CNY | -41.7% |
| 2012 | 61.77 Million CNY | -22.89% |
| 2011 | 83.42 Million CNY | 13.11% |
| 2010 | 71.66 Million CNY | 30.78% |
| 2009 | 54.5 Million CNY | 34.66% |
| 2008 | 40.84 Million CNY | 9.39% |
| 2007 | 36.43 Million CNY | 9.7% |
| 2006 | 34.11 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 65.38 Million CNY | -40.81% |
| 2024 Q1 | 87.19 Million CNY | 17.71% |
| 2024 Q3 | 64.47 Million CNY | -1.39% |
| 2023 Q3 | 64.86 Million CNY | 26.16% |
| 2023 Q2 | 51.41 Million CNY | 0.01% |
| 2023 Q1 | 51.4 Million CNY | -30.37% |
| 2023 FY | - CNY | 14.93% |
| 2023 Q4 | 66.37 Million CNY | 2.33% |
| 2022 Q4 | 73.82 Million CNY | 25.27% |
| 2022 Q3 | 58.93 Million CNY | 35.35% |
| 2022 Q2 | 43.54 Million CNY | 71.71% |
| 2022 Q1 | 25.35 Million CNY | -70.72% |
| 2022 FY | - CNY | 1.15% |
| 2021 Q3 | 36.5 Million CNY | -34.6% |
| 2021 Q1 | 24.95 Million CNY | -65.94% |
| 2021 Q4 | 86.61 Million CNY | 137.29% |
| 2021 FY | - CNY | 36.38% |
| 2021 Q2 | 55.81 Million CNY | 123.69% |
| 2020 Q2 | 982.89 Thousand CNY | -96.97% |
| 2020 Q4 | 73.24 Million CNY | 222.72% |
| 2020 Q3 | 22.69 Million CNY | 2209.21% |
| 2020 FY | - CNY | 11.67% |
| 2020 Q1 | 32.39 Million CNY | -40.13% |
| 2019 Q2 | 31.35 Million CNY | 68.15% |
| 2019 FY | - CNY | -0.69% |
| 2019 Q1 | 18.64 Million CNY | -23.02% |
| 2019 Q3 | 22.8 Million CNY | -27.29% |
| 2019 Q4 | 54.1 Million CNY | 137.28% |
| 2018 FY | - CNY | -15.87% |
| 2018 Q2 | 59.18 Million CNY | 94.97% |
| 2018 Q3 | 20.51 Million CNY | -65.33% |
| 2018 Q1 | 30.35 Million CNY | -51.22% |
| 2018 Q4 | 24.22 Million CNY | 18.06% |
| 2017 Q2 | 48.47 Million CNY | 154.51% |
| 2017 FY | - CNY | -5.49% |
| 2017 Q4 | 62.23 Million CNY | 120.52% |
| 2017 Q3 | 28.22 Million CNY | -41.78% |
| 2017 Q1 | 19.04 Million CNY | -80.59% |
| 2016 Q1 | 13.54 Million CNY | -77.89% |
| 2016 Q4 | 98.15 Million CNY | 213.8% |
| 2016 FY | - CNY | 51.49% |
| 2016 Q3 | 31.27 Million CNY | -37.13% |
| 2016 Q2 | 49.75 Million CNY | 267.42% |
| 2015 FY | - CNY | -10.97% |
| 2015 Q4 | 61.24 Million CNY | 278.17% |
| 2015 Q2 | 43.63 Million CNY | 366.44% |
| 2015 Q1 | 9.35 Million CNY | -84.74% |
| 2015 Q3 | 16.19 Million CNY | -62.88% |
| 2014 Q2 | 11.45 Million CNY | -6.25% |
| 2014 FY | - CNY | 345.41% |
| 2014 Q4 | 61.3 Million CNY | 35.43% |
| 2014 Q3 | 45.27 Million CNY | 295.3% |
| 2014 Q1 | 12.21 Million CNY | 1649.34% |
| 2013 Q3 | 11.87 Million CNY | 146.7% |
| 2013 Q4 | 698.31 Thousand CNY | -94.12% |
| 2013 FY | - CNY | -41.7% |
| 2013 Q1 | 5.21 Million CNY | 10.54% |
| 2013 Q2 | 4.81 Million CNY | -7.76% |
| 2012 FY | - CNY | -22.89% |
| 2012 Q2 | 19.48 Million CNY | 66.79% |
| 2012 Q3 | 17.4 Million CNY | -10.72% |
| 2012 Q1 | 11.68 Million CNY | -71.08% |
| 2012 Q4 | 4.72 Million CNY | -72.87% |
| 2011 Q3 | 9.26 Million CNY | -53.22% |
| 2011 Q1 | 8.2 Million CNY | -65.23% |
| 2011 Q2 | 19.8 Million CNY | 141.29% |
| 2011 Q4 | 40.4 Million CNY | 336.16% |
| 2011 FY | - CNY | 13.11% |
| 2010 Q1 | 9.96 Million CNY | -15.06% |
| 2010 Q2 | 24.09 Million CNY | 141.91% |
| 2010 Q3 | 11.62 Million CNY | -51.75% |
| 2010 FY | - CNY | 30.78% |
| 2010 Q4 | 23.6 Million CNY | 103.02% |
| 2009 Q3 | 11.96 Million CNY | -27.92% |
| 2009 Q1 | 6.07 Million CNY | -43.23% |
| 2009 FY | - CNY | 34.66% |
| 2009 Q4 | 11.72 Million CNY | -1.95% |
| 2009 Q2 | 16.59 Million CNY | 173.23% |
| 2008 FY | - CNY | 9.39% |
| 2008 Q4 | 10.69 Million CNY | 103.28% |
| 2008 Q3 | 5.26 Million CNY | 0.0% |
| 2007 FY | - CNY | 9.7% |
| 2006 FY | - CNY | 0.0% |